Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

41. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (PubMed)

Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin 19608026 2009 07 17 2009 08 31 2016 11 25 1558-3597 54 4 2009 Jul 21 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome (...) : a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). 293-302 10.1016/j.jacc.2009.04.033 The objective of this study was to evaluate whether the regressive effects of aggressive lipid-lowering therapy with atorvastatin on coronary plaque volume (PV) in patients with acute coronary syndrome (ACS) are generalized for other statins in multicenter

Full Text available with Trip Pro

2009 EvidenceUpdates

42. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) (PubMed)

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) 19539078 2009 06 22 2009 07 14 2015 11 19 1879-1913 103 12 2009 Jun 15 The American journal of cardiology Am. J. Cardiol. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). 1694-702 10.1016/j.amjcard.2009.05.003 (...) Patients with the metabolic syndrome are at an increased risk of cardiovascular disease and might require intensive lipid therapy. Many patients remain at the starting dose of lipid therapy and might not be titrated up to a higher dose. The present double-blind, randomized, 6-week study assessed the lipid-lowering efficacy of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 or 20 mg, and ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in 1,128 patients with hypercholesterolemia and the

2009 EvidenceUpdates

43. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction (PubMed)

Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction 19427432 2009 05 11 2009 06 05 2015 11 19 1879-1913 103 10 2009 May 15 The American journal of cardiology Am. J. Cardiol. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. 1381-5 10.1016/j.amjcard (...) .2009.01.377 We investigated whether intensive cholesterol lowering could more effectively prevent heart failure (HF) in secondary prevention. The IDEAL study was a 4.8-year prospective, randomized trial comparing "usual" simvastatin treatment (20 to 40 mg/day, n = 4,449) with high-dose atorvastatin (80 mg/day, n = 4,439) in patients with a history of myocardial infarction (MI). At baseline, 94% of patients (n = 8,351) had no history of HF. During the course of the trial, there were 222 new or recurrent

2009 EvidenceUpdates

44. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (PubMed)

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease 19231315 2009 02 23 2009 03 27 2015 11 19 1879-1913 103 5 2009 Mar 01 The American journal of cardiology Am. J. Cardiol. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering (...) [IDEAL] study). 577-82 10.1016/j.amjcard.2008.10.029 The efficacy and safety of atorvastatin (80 mg/day) versus simvastatin (20 to 40 mg/day) in older (age >or=65 years) versus younger (<65 years) patients were assessed in a prespecified secondary analysis of the 8,888 patients with myocardial infarction in the IDEAL trial, a randomized open-label study. Several cardiovascular end points were evaluated, including the occurrence of a first major coronary event (MCE; nonfatal myocardial infarction

2009 EvidenceUpdates

45. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia (PubMed)

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia 19195513 2009 02 06 2009 03 19 2015 11 19 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. 515-22 10.1016/j.amjcard.2008.10.025 In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased (...) high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol <40 mg/dl for men and <50 mg/dl for women were randomly assigned

2009 EvidenceUpdates

46. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event (PubMed)

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event 19195498 2009 02 06 2009 03 19 2016 12 15 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. 437-41 10.1016/j.amjcard.2008.10.008 In addition to inhibiting (...) to inhibit ROCK activity. Accordingly, we enrolled 30 men with stable atherosclerosis (low-density lipoprotein [LDL] > or =100 mg/dL) in a randomized, double-blind study comparing equivalent LDL-lowering doses of a hydrophilic statin (rosuvastatin 10 mg once a day) with a lipophilic statin (atorvastatin 40 mg once a day) for 28 days. We assessed the change in lipids, ROCK activity, and flow-mediated dilation (FMD) of the brachial artery before and after statin therapy. Both treatment groups exhibited

Full Text available with Trip Pro

2009 EvidenceUpdates

47. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease (PubMed)

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease 19026302 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary (...) heart disease. 1489-94 10.1016/j.amjcard.2008.09.075 The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg. In this 6-week, multicenter, double-blind, randomized, parallel-group study, 196 patients treated with atorvastatin 20

2009 EvidenceUpdates

48. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease (PubMed)

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease 19026303 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary (...) heart disease. 1495-501 10.1016/j.amjcard.2008.09.076 The percentage of change from baseline in low-density lipoprotein (LDL) cholesterol after the addition of ezetimibe 10 mg to atorvastatin 40 mg was compared with uptitration to atorvastatin 80 mg. In this multicenter, double-blind, parallel-group study, adult hypercholesterolemic patients using atorvastatin 40 mg/day were randomly assigned to atorvastatin 40 mg plus ezetimibe 10 mg or uptitration to atorvastatin 80 mg. After 6 weeks of treatment, compared

2009 EvidenceUpdates

49. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma (PubMed)

Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma 18757458 2008 11 21 2009 02 23 2015 11 19 1468-3296 63 12 2008 Dec Thorax Thorax Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. 1070-5 10.1136/thx.2008.100198 Statins have anti-inflammatory properties that may be beneficial in the treatment of asthma. A study was undertaken to test the hypothesis that atorvastatin (...) added to inhaled corticosteroids improves lung function and airway inflammation in atopic adults with asthma. 54 adults with atopic asthma were recruited to a double-blind randomised controlled crossover trial comparing the effect of oral atorvastatin 40 mg daily with that of a matched placebo on asthma control and airway inflammation. Each treatment was administered for 8 weeks separated by a 6-week washout period. The primary outcome was morning peak expiratory flow (PEF). Secondary outcomes

Full Text available with Trip Pro

2009 EvidenceUpdates

50. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial (...) Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions

2009 NHS Economic Evaluation Database.

51. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared (...) with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, Anglo-Scandinavian Cardiac Outcomes Trial investigators Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2009 NHS Economic Evaluation Database.

52. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea

Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine (...) and atorvastatin for the primary prevention of cardiovascular disease in Korea Liew D, Park HJ, Ko SK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of a single-tablet fixed-dose combination of amlodipine

2009 NHS Economic Evaluation Database.

53. Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada

Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Khoury H, Wagner M, Merikle E, Johnson SJ, Roberts C Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes. The authors concluded that their study supported the cost-effectiveness

2009 NHS Economic Evaluation Database.

54. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials (PubMed)

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials 19064019 2008 12 09 2008 12 18 2015 11 19 1879-1913 102 12 2008 Dec 15 The American journal of cardiology Am. J. Cardiol. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. 1654-62 10.1016/j.amjcard.2008.08.014 The benefit from statin therapy is proportional (...) to the low-density lipoprotein (LDL) cholesterol reduction. However, adverse events appear to be related to dose rather than LDL cholesterol reduction. Although serious side effects are rare, any comparison of statins requires scrutiny of the relation between therapeutic effect and risk of side effects. This report sought to determine whether the additional LDL cholesterol lowering with rosuvastatin over atorvastatin could be obtained without increased risk of short-term adverse events. Twenty-five studies (approximately

2009 EvidenceUpdates

55. Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease

Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease Article Text Therapeutics Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable

2008 Evidence-Based Medicine (Requires free registration)

56. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes Ramsey S D, Clarke L D, Roberts C S, Sullivan S D, Johnson S J, Liu L Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study determined the cost-effectiveness of atorvastatin, compared with no statin therapy, for the primary prevention of cardiovascular (CV) events in patients with Type 2 diabetes, normal low-density lipoprotein cholesterol, no history of CV disease, but one additional risk factor for CV

2008 NHS Economic Evaluation Database.

57. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

2008 NHS Economic Evaluation Database.

58. Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy

Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Alonso R, Fernandez de Bobadilla J, Mendez I, Lazaro P, Mata N, Mata P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of various preventive lifetime lipid-lowering interventions for patients with a genetic diagnosis of familial hypercholesterolaemia. The authors concluded that atorvastatin 80mg monotherapy was cost-effective and the addition of ezetimibe led

2008 NHS Economic Evaluation Database.

59. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Usher-Smith J (...) A, Ramsbottom T, Pearmain H, Kirby M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined switching the patients' medication from 10 or 20g atorvastatin to 20 or 40 mg simvastatin for the treatment of high cholesterol, and

2007 NHS Economic Evaluation Database.

60. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario

Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Araujo D V, Bahia L (...) , Souza C P, Pavao A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of rosuvastatin versus atorvastatin for lowering low-density lipoprotein-cholesterol and avoiding future cardiovascular

2007 NHS Economic Evaluation Database.